Breast-Cancer Tumor Localization and Sizing by Functional Diffuse Optical Tomographic Imaging Combined with Controlled Compression Protocols

2014 ◽  
Author(s):  
Randall L. Barbour ◽  
Rabah M. Al abdi ◽  
Yong Xu ◽  
Harry L. Graber
Keyword(s):  
Breast Cancer ◽  
Tomographic Imaging ◽  
Tumor Localization ◽  
Cancer Tumor

scholarly journals Fat Composition Measured by Proton Spectroscopy: A Breast Cancer Tumor Marker?

Diagnostics ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 564
Author(s):  
Almir Bitencourt ◽  
Varadan Sevilimedu ◽  
Elizabeth A. Morris ◽  
Katja Pinker ◽  
Sunitha B. Thakur
Keyword(s):  
Breast Cancer ◽  
Saturation Index ◽  
Multivariable Analysis ◽  
Area Under The Curve ◽  
Resonance Spectroscopy ◽  
Breast Cancers ◽  
Her2 Positive ◽  
Tumor Tissues ◽  
Cancer Tumor ◽  
Fat Composition

Altered metabolism including lipids is an emerging hallmark of breast cancer. The purpose of this study was to investigate if breast cancers exhibit different magnetic resonance spectroscopy (MRS)-based lipid composition than normal fibroglandular tissue (FGT). MRS spectra, using the stimulated echo acquisition mode sequence, were collected with a 3T scanner from patients with suspicious lesions and contralateral normal tissue. Fat peaks at 1.3 + 1.6 ppm (L13 + L16), 2.1 + 2.3 ppm (L21 + L23), 2.8 ppm (L28), 4.1 + 4.3 ppm (L41 + L43), and 5.2 + 5.3 ppm (L52 + L53) were quantified using LCModel software. The saturation index (SI), number of double bods (NBD), mono and polyunsaturated fatty acids (MUFA and PUFA), and mean chain length (MCL) were also computed. Results showed that mean concentrations of all lipid metabolites and PUFA were significantly lower in tumors compared with that of normal FGT (p ≤ 0.002 and 0.04, respectively). The measure best separating normal and tumor tissues after adjusting with multivariable analysis was L21 + L23, which yielded an area under the curve of 0.87 (95% CI: 0.75–0.98). Similar results were obtained between HER2 positive versus HER2 negative tumors. Hence, MRS-based lipid measurements may serve as independent variables in a multivariate approach to increase the specificity of breast cancer characterization.

Vitamin E Succinate Promotes Breast Cancer Tumor Dormancy

2000 ◽  
Vol 93 (1) ◽  
pp. 163-170 ◽  
Author(s):  
Mokenge P. Malafa ◽  
Leslie T. Neitzel
Keyword(s):  
Breast Cancer ◽  
Vitamin E ◽  
Tumor Dormancy ◽  
Vitamin E Succinate ◽  
Cancer Tumor

Efficacy of DAN-222, a novel investigational polymeric nanoparticle with topoisomerase I inhibitor, as monotherapy in breast cancer models and when combined with PARP inhibitor.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 1081-1081
Author(s):  
Ashley P Wright ◽  
Jodi D Bradley ◽  
Timothy Hagerty ◽  
Emily A Wyatt
Keyword(s):  
Breast Cancer ◽  
Tumor Growth ◽  
Growth Inhibition ◽  
Tumor Cells ◽  
Topoisomerase I ◽  
Parp Inhibitor ◽  
Parp Inhibitors ◽  
Topoisomerase I Inhibitor ◽  
Polymeric Nanoparticle ◽  
Cancer Tumor

1081 Background: Patients with BRCA-positive HER2-negative breast cancer benefit from PARP inhibitor therapy, but additional benefit is still desired. PARP inhibition alone does not prevent all mechanisms for repairing damage to DNA such as homologous recombination repair. An attractive combination for treating such patients would be combining a topoisomerase I inhibitor with a PARP inhibitor given the dual mechanism this would provide for DNA damage and inhibited repair, leading to tumor cell death. This combination has been tried in multiple phase 1 studies, but myelotoxicity prevented the combination from being evaluated further. DAN-222 is a novel investigational polymeric nanoparticle conjugated with camptothecin, a topoisomerase I inhibitor, that provides significant accumulation of drug in tumor tissues via the enhanced permeability and retention (EPR) effect and significantly reduced bone marrow exposure compared to native chemotherapy. These observations underscore the potential advantages of DAN-222 alone as well as in combination with other agents such as PARP inhibitors in solid tumors. Here, we report the effects of DAN-222 monotherapy and in combination with a PARP inhibitor on the growth inhibition in an HRD+ TNBC breast cancer (MDA-MB-436) and an HRD- ovarian (OVCAR3) xenograft mouse model. Methods: HRD+ breast cancer tumor cells (MDA-MB-436) were implanted into female NCr nu/nu mice and HRD- ovarian cancer tumor cells (OVCAR3) were implanted into female CB.17 SCID mice. Mice were randomized to vehicle or treatment arms until tumors reached 2000 mm3 or day 45 (MDA-MB-436) or 1000mm3 or day 45 (OVCAR3). The groups evaluated include multiple dose levels of DAN-222 as monotherapy and those also combined with niraparib. Results: Results were consistent in both the HRD+ and HRD- tumor models with profound dose-response of DAN-222 monotherapy inhibiting tumor growth. Additionally, synergy was demonstrated when DAN-222 was combined with niraparib, clearly evident with low doses of both products when used in combination. The table below highlights the synergy of the combination of DAN-222 at 0.3 mg/kg and niraparib at 25 mg/kg above each agent alone on the tumor growth inhibition in the MDA-MB-436 xenograft. Conclusions: Combining a PARP inhibitor with a topoisomerase I inhibitor delivered via this polymeric nanoparticle delivery system (DAN-222) has synergistic efficacy in both HRD+ and HRD- xenograft tumor models. These data support continued development of DAN-222 to treat solid tumors and its combination use with PARP inhibitors.[Table: see text]

scholarly journals Selective Small Molecule Stat3 Inhibitor Reduces Breast Cancer Tumor-Initiating Cells and Improves Recurrence Free Survival in a Human-Xenograft Model

PLoS ONE ◽  
2012 ◽  
Vol 7 (8) ◽  
pp. e30207 ◽  
Author(s):  
Bhuvanesh Dave ◽  
Melissa D. Landis ◽  
Lacey E. Dobrolecki ◽  
Meng-Fen Wu ◽  
Xiaomei Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Small Molecule ◽  
Xenograft Model ◽  
Recurrence Free Survival ◽  
Tumor Initiating Cells ◽  
Free Survival ◽  
Cancer Tumor
Sign in / Sign up

Export Citation Format

Share Document